why choose us

First received: December 14, 2023

Clinical Trial: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Thyroid Eye Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Brief Summary: LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).The primary and secondary objectives of this study are to evaluate the safety, treatment effect, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.

Read more